Bioengineer

Epigenetic editing, which alters gene activity without changing DNA sequence, is reportedly approaching clinical application as bioengineering tools mature. Advances in gene-regulation technologies are making it feasible to target epigenetic marks precisely, opening the door to therapies for diseases rooted in gene expression rather than genetic mutations. The development signals a shift from laboratory research toward translational medicine, with researchers watching how safety and delivery challenges are addressed.